Hélène Sabatel, PhD, is a distinguished member of the Artialis Board of Directors, bringing a wealth of expertise in molecular biology, technology transfer, and life sciences investment. Dr. Sabatel earned her doctorate in molecular biology, focusing her research on the signaling pathways activated in response to chemotherapeutic treatments in cancer cells. Complementing her scientific background, she also holds a master’s degree in management, equipping her with a unique blend of scientific and business acumen.

Her professional journey includes over eight years at the technology transfer office of the University of Liège, where she managed intellectual property, negotiated collaboration and license agreements, and supported the establishment of spin-offs. This role underscored her commitment to bridging the gap between academic research and industry applications.

Currently, she serves as an Investment Manager at Noshaq, a prominent investment firm in Belgium. In this capacity, she oversees several of Noshaq’s holdings in biotech companies, providing strategic guidance and support. Her role extends to board positions at various life sciences companies, including Amyl Therapeutics and Allegro.bio, where she contributes to shaping the future of biotech innovations.

Dr. Sabatel’s extensive experience and dedication to advancing life sciences make her an invaluable asset to Artialis, where she continues to contribute to the company’s strategic direction and growth.